Cargando…
Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent
A novel bacteriophage CUB19 specific to the bacterial species Stenotrophomonas maltophilia was isolated from hospital sewage and characterized as a new species belonging to a proposed new phage genus ‘Cubvirus’ (Caudoviricetes). Its genome contains a total of 48,301 bp and 79 predicted genes, among...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612306/ https://www.ncbi.nlm.nih.gov/pubmed/36297651 http://dx.doi.org/10.3390/pharmaceutics14102216 |
_version_ | 1784819742227300352 |
---|---|
author | Fanaei Pirlar, Rima Wagemans, Jeroen Kunisch, Fabian Lavigne, Rob Trampuz, Andrej Gonzalez Moreno, Mercedes |
author_facet | Fanaei Pirlar, Rima Wagemans, Jeroen Kunisch, Fabian Lavigne, Rob Trampuz, Andrej Gonzalez Moreno, Mercedes |
author_sort | Fanaei Pirlar, Rima |
collection | PubMed |
description | A novel bacteriophage CUB19 specific to the bacterial species Stenotrophomonas maltophilia was isolated from hospital sewage and characterized as a new species belonging to a proposed new phage genus ‘Cubvirus’ (Caudoviricetes). Its genome contains a total of 48,301 bp and 79 predicted genes, among which some have been associated with packaging and lysis-associated proteins, structural proteins, or DNA- and metabolism-associated proteins. No lysogeny-associated proteins or known virulence proteins were identified on the phage genome. CUB19 showed stability over a wide range of temperatures (−20 °C–60 °C) and pH values (pH 3–pH 13). Despite its narrow host range, this phage has potent observed antimicrobial and antibiofilm activity. A time-killing curve assay showed significant biofilm reduction after 24 h exposure to CUP19. Isothermal microcalorimetry assays investigating phage-antibiotic combinations revealed the effectiveness of CUB19 during co-administration with increasing antibiotic doses, regardless of the administration approach (simultaneous or staggered). These are encouraging indications for its application as a targeted therapeutic agent against resilient biofilm-associated Stenotrophomonas infections. |
format | Online Article Text |
id | pubmed-9612306 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96123062022-10-28 Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent Fanaei Pirlar, Rima Wagemans, Jeroen Kunisch, Fabian Lavigne, Rob Trampuz, Andrej Gonzalez Moreno, Mercedes Pharmaceutics Article A novel bacteriophage CUB19 specific to the bacterial species Stenotrophomonas maltophilia was isolated from hospital sewage and characterized as a new species belonging to a proposed new phage genus ‘Cubvirus’ (Caudoviricetes). Its genome contains a total of 48,301 bp and 79 predicted genes, among which some have been associated with packaging and lysis-associated proteins, structural proteins, or DNA- and metabolism-associated proteins. No lysogeny-associated proteins or known virulence proteins were identified on the phage genome. CUB19 showed stability over a wide range of temperatures (−20 °C–60 °C) and pH values (pH 3–pH 13). Despite its narrow host range, this phage has potent observed antimicrobial and antibiofilm activity. A time-killing curve assay showed significant biofilm reduction after 24 h exposure to CUP19. Isothermal microcalorimetry assays investigating phage-antibiotic combinations revealed the effectiveness of CUB19 during co-administration with increasing antibiotic doses, regardless of the administration approach (simultaneous or staggered). These are encouraging indications for its application as a targeted therapeutic agent against resilient biofilm-associated Stenotrophomonas infections. MDPI 2022-10-18 /pmc/articles/PMC9612306/ /pubmed/36297651 http://dx.doi.org/10.3390/pharmaceutics14102216 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fanaei Pirlar, Rima Wagemans, Jeroen Kunisch, Fabian Lavigne, Rob Trampuz, Andrej Gonzalez Moreno, Mercedes Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent |
title | Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent |
title_full | Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent |
title_fullStr | Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent |
title_full_unstemmed | Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent |
title_short | Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent |
title_sort | novel stenotrophomonas maltophilia bacteriophage as potential therapeutic agent |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612306/ https://www.ncbi.nlm.nih.gov/pubmed/36297651 http://dx.doi.org/10.3390/pharmaceutics14102216 |
work_keys_str_mv | AT fanaeipirlarrima novelstenotrophomonasmaltophiliabacteriophageaspotentialtherapeuticagent AT wagemansjeroen novelstenotrophomonasmaltophiliabacteriophageaspotentialtherapeuticagent AT kunischfabian novelstenotrophomonasmaltophiliabacteriophageaspotentialtherapeuticagent AT lavignerob novelstenotrophomonasmaltophiliabacteriophageaspotentialtherapeuticagent AT trampuzandrej novelstenotrophomonasmaltophiliabacteriophageaspotentialtherapeuticagent AT gonzalezmorenomercedes novelstenotrophomonasmaltophiliabacteriophageaspotentialtherapeuticagent |